Abstract
Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.
Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.
Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95% CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95% CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95% CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 % CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95% CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95% CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95% CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95% CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.
Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.